Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824236 | 0.89 | DRD2 (0.36) | DRD2MCHR1DRD4DRD3CCR2 | |
| SCHEMBL13824430 | 0.88 | DRD2 (0.35) | LTA4HDRD2MCHR1DRD4DRD3 | |
| SCHEMBL12121932 | 0.88 | DRD2 (0.36) | DRD2DRD4DRD3CCR2 | |
| SCHEMBL13824482 | 0.87 | DRD2 (0.40) | CHRM2CCR1CCR5DRD2HRH1 | |
| SCHEMBL13824224 | 0.86 | MCHR1 (0.34) | CHRM2CCR1CCR5DRD2MCHR1 | |
| SCHEMBL13617241 | 0.85 | DRD2 (0.39) | DRD2MCHR1DRD4DRD3CCR2 | |
| SCHEMBL13617082 | 0.84 | DRD2 (0.39) | DRD2MCHR1DRD4DRD3CCR2 | |
| SCHEMBL12121936 | 0.83 | HTR2A (0.37) | DRD2MCHR1DRD4DRD3CCR2 | |
| SCHEMBL12121934 | 0.77 | DRD2 (0.36) | DRD2MCHR1DRD4DRD3 | |
| SCHEMBL10287605 | 0.77 | DRD2 (0.41) | CCR1DRD2HRH1DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | CHRM2 747/4885CCR1 9/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.